Bioactive lipids and chronic inflammation: Managing the fire within

Frontiers in Immunology

Volumn 9, Issue JAN, 2018, Pages

  Chiurchiù, Valerio ^a,b   Leuti, Alessandro ^a,b   Maccarrone, Mauro ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Eicosanoids; Endocannabinoids; Inflammation; Resolution; Specialized proresolving mediators; Sphingolipids

Indexed keywords

ANANDAMIDE; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ENDOCANNABINOID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; GLYCEROPHOSPHOLIPID; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; LIPID; LIPOPROTEIN LIPASE; LIPOXIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; SPHINGOLIPID; TRANSIENT RECEPTOR POTENTIAL CHANNEL;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; HUMAN; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; MALIGNANT NEOPLASM; MEDIATOR; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 85041350359     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00038     Document Type: Review

References (140)

1. Majno G, Joris I. Cells, Tissues, and Disease. Principles of General Pathology. II ed. Oxford: Oxford University Press (2004).
2. Kumar V, Abbas A, Aster J. Robbins & Cotran Pathologic Basis of Disease. IX ed. Amsterdam: Elsevier (2014).
3. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol (2009) 49:123-50. doi:10.1146/annurev.pharmtox.011008.145616
4. Chiurchiù V, Maccarrone M. Bioactive lipids as modulators of immunity, inflammation and emotions. Curr Opin Pharmacol (2016) 29:54-62. doi:10.1016/j.coph.2016.06.005
5. Nathan C. Points of control in inflammation. Nature (2002) 420:846-52. doi:10.1038/nature01320
6. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature (2014) 510:92-101. doi:10.1038/nature13479
7. Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol (2016) 16:51-67. doi:10.1038/nri.2015.4
8. Nathan C, Ding A. Nonresolving inflammation. Cell (2010) 140:871-82. doi:10.1016/j.cell.2010.02.029
9. El Alwani M, Wu BX, Obeid LM, Hannun YA. Bioactive sphingolipids in the modulation of the inflammatory response. Pharmacol Ther (2006) 112:171-83. doi:10.1016/j.pharmthera.2006.04.004
10. Chiurchiù V, Battistini L, Maccarrone M. Endocannabinoid signalling in innate and adaptive immunity. Immunology (2015) 144:352-64. doi:10.1111/imm.12441
11. Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov (2016) 15:551-67. doi:10.1038/nrd.2016.39
12. Aoki T, Narumiya S. Prostaglandins and chronic inflammation. Trends Pharmacol Sci (2012) 33:304-11. doi:10.1016/j.tips.2012.02.004
13. Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol (2015) 15:511-23. doi:10.1038/nri3859
14. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem (2000) 69:145-82. doi:10.1146/annurev.biochem.69.1.145
15. Stitham J, Midgett C, Martin KA, Hwa J. Prostacyclin: an inflammatory paradox. Front Pharmacol (2011) 11:517-28. doi:10.3389/fphar.2011.00024
16. Kihara Y, Gupta S, Maurya MR, Armando A, Shah I, Quehenberger O, et al. Modeling of eicosanoid fluxes reveals functional coupling between cyclooxygenases and terminal synthases. Biophys J (2014) 106:966-75. doi:10.1016/j.bpj.2014.01.015
17. Mandal AK, Jones PB, Bair AM, Christmas P, Miller D, Ting-ting DY, et al. The nuclear membrane organization of leukotriene synthesis. Proc Natl Acad Sci U S A (2008) 105:20434-9. doi:10.1073/pnas.0808211106
18. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol (2011) 31:986-1000. doi:10.1161/ATVBAHA.110.207449
19. Vane JR. Biomedicine. Back to an aspirin a day? Science (2002) 296:474-5. doi:10.1126/science.1071702
20. Narumiya S, Furuyashiki T. Fever, inflammation, pain and beyond: prostanoid receptor research during these 25 years. FASEB J (2011) 25:813-8. doi:10.1096/fj.11-0302ufm
21. Honda T, Segi-Nishida E, Miyachi Y, Narumiya S. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med (2006) 203:325-35. doi:10.1084/jem.20051310
22. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med (2001) 7:1048-51. doi:10.1038/nm0901-1048
23. Hirata T, Narumiya S. Prostanoids as regulators of innate and adaptive immunity. Adv Immunol (2012) 116:143-74. doi:10.1016/B978-0-12-394300-2.00005-3
24. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med (2009) 15:633-40. doi:10.1038/nm.1968
25. Chen Q, Muramoto K, Masaaki N, Ding Y, Yang H, Mackey M, et al. A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol (2010) 160:292-310. doi:10.1111/j.1476-5381.2010.00647
26. Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 3:e58. doi:10.1371/journal.pgen.0030058
27. Oguma T, Palmer LJ, Birben E, Sonna LA, Asano K, Lilly CM. Role of prostanoid DP receptor variants in susceptibility to asthma. N Engl J Med (2004) 351:1752-63. doi:10.1056/NEJMoa031785
28. Tajouri L, Fernandez F, Griffiths LR. Gene expression studies in multiple sclerosis. Curr Genomics (2007) 8:181-9. doi:10.2174/138920207780833829
29. Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, Moutsianas L, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 476:214-9. doi:10.1038/nature10251
30. Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun (2016) 7:12859. doi:10.1038/ncomms12859
31. De Caterina R, Zampolli A. From asthma to atherosclerosis -5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med (2004) 350:4-7. doi:10.1056/NEJMp038190
32. Lee W, Su Kim H, Lee GR. Leukotrienes induce the migration of Th17 cells. Immunol Cell Biol (2015) 93:472-9. doi:10.1038/icb.2014.104
33. Powell WS, Rokach J. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochim Biophys Acta (2015) 1851:340-55. doi:10.1016/j.bbalip.2014.10.008
34. Dalli J, Chiang N, Serhan CN. Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat Med (2015) 21:1071-5. doi:10.1038/nm.3911
35. Serhan CN, Chiang N, Dalli J. New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Mol Aspects Med (2017). doi:10.1016/j.mam.2017.08.002
36. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids (2005) 73:163-77. doi:10.1016/j.plefa.2005.05.003
37. Buckley C, Gilroy D, Serhan C. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity (2014) 40:315-27. doi:10.1016/j.immuni.2014.02.009
38. Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med (2017). doi:10.1016/j.mam.2017.03.005
39. Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J Immunol (2012) 189:1036-42. doi:10.4049/jimmunol.1103483
40. Kim N, Ramon S, Thatcher TH, Woeller CF, Sime PJ, Phipps RP. Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production. Eur J Immunol (2016) 46:81-91. doi:10.1002/eji.201545673
41. Ariel A, Chiang N, Arita M, Petasis NA, Serhan CN. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol (2003) 170:6266-72. doi:10.4049/jimmunol.170.12.6266
42. Spurr L, Nadkarni S, Pederzoli-Ribeil M, Goulding NJ, Perretti M, D'Acquisto F. Comparative analysis of annexin A1-formyl peptide receptor 2/ALX expression in human leukocyte subsets. Int Immunopharmacol (2011) 11:55-66. doi:10.1016/j.intimp.2010.10.006
43. Chiurchiù V, Leuti A, Dalli J, Jacobsson A, Battistini L, Maccarrone M, et al. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci Transl Med (2016) 8:353ra111. doi:10.1126/scitranslmed.aaf7483
44. Settimio R, Clara DF, Franca F, Francesca S, Michele D. Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis. Mediators Inflamm (2012) 2012:318621. doi:10.1155/2012/318621
45. Kim T-H, Kim G-D, Jin Y-H, Park YS, Park C-S. Omega-3 fatty acid-derived mediator, resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int Immunopharmacol (2012) 14:384-91. doi:10.1016/j.intimp.2012.08.005
46. Ariel A, Li P-L, Wang W, Tang W-X, Fredman G, Hong S, et al. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem (2005) 280:43079-86. doi:10.1074/jbc.M509796200
47. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 178:496-502. doi:10.4049/jimmunol.178.1.496
48. Hsiao H-M, Thatcher TH, Colas RA, Serhan CN, Phipps RP, Sime PJ. Resolvin D1 reduces emphysema and chronic inflammation. Am J Pathol (2015) 185:3189-201. doi:10.1016/j.ajpath.2015.08.008
49. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J (2011) 25:2399-407. doi:10.1096/fj.10-178657
50. Clària J, Dalli J, Yacoubian S, Gao F, Serhan CN. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol (2012) 189:2597-605. doi:10.4049/jimmunol.1201272
51. Perretti M, Norling LV. Actions of SPM in regulating host responses in arthritis. Mol Aspects Med (2017) 58:57-64. doi:10.1016/j.mam.2017.04.005
52. Norling LV, Headland SE, Dalli J, Arnardottir HH, Haworth O, Jones HR, et al. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight (2016) 1:e85922. doi:10.1172/jci.insight.85922
53. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 22:3595-606. doi:10.1096/fj.08-112201
54. Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AHK, Pande R, et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol (2010) 177:2116-23. doi:10.2353/ajpath.2010.091082
55. Hasturk H, Abdallah R, Kantarci A, Nguyen D, Giordano N, Hamilton J, et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol (2015) 35:1123-33. doi:10.1161/ATVBAHA.115.305324
56. Salic K, Morrison MC, Verschuren L, Wielinga PY, Wu L, Kleemann R, et al. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis (2016) 250:158-65. doi:10.1016/j.atherosclerosis.2016.05.001
57. Viola JR, Lemnitzer P, Jansen Y, Csaba G, Winter C, Neideck C, et al. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ Res (2016) 119:1030-8. doi:10.1161/CIRCRESAHA.116.309492
58. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol (2011) 187:1957-69. doi:10.4049/jimmunol.1101305
59. Schwanke RC, Marcon R, Bento AF, Calixto JB. EPA-and DHA-derived resolvins' actions in inflammatory bowel disease. Eur J Pharmacol (2016) 785:156-64. doi:10.1016/j.ejphar.2015.08.050
60. Wang X, Zhu M, Hjorth E, Cortés-Toro V, Eyjolfsdottir H, Graff C, et al. Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement (2015) 11:40.e-50.e. doi:10.1016/j.jalz.2013.12.024
61. Zhu M, Wang X, Hjorth E, Colas RA, Schroeder L, Granholm A-C, et al. Pro-resolving lipid mediators improve neuronal survival and increase Aß42 phagocytosis. Mol Neurobiol (2016) 53:2733-49. doi:10.1007/s12035-015-9544-0
62. Mizwicki MT, Liu G, Fiala M, Magpantay L, Sayre J, Siani A, et al. 1a,25-Dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-ß phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis (2013) 34:155-70. doi:10.3233/JAD-121735
63. Fiala M, Terrando N, Dalli J. Specialized pro-resolving mediators from omega-3 fatty acids improve amyloid-ß phagocytosis and regulate inflammation in patients with minor cognitive impairment. J Alzheimers Dis (2015) 48:293-301. doi:10.3233/JAD-150367
64. Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, et al. ω-3 supplementation increases amyloid-ß phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J (2015) 29:2681-9. doi:10.1096/fj.14-264218
65. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis (2012) 1:60-74.
66. Poisson LM, Suhail H, Singh J, Datta I, Denic A, Labuzek K, et al. Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis. J Biol Chem (2015) 290:30697-712. doi:10.1074/jbc.M115.679068
67. Serhan CN. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med (2017) 2997(17):30018-30013. doi:10.1016/j.mam.2017.03.001
68. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol (2008) 9:139-50. doi:10.1038/nrm2329
69. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res (2009) 50:S91-6. doi:10.1194/jlr.R800080-JLR200
70. Shindou H, Hishikawa D, Harayama T, Eto M, Shimizu T. Generation of membrane diversity by lysophospholipid acyltransferases. J Biochem (2013) 154:21-8. doi:10.1093/jb/mvt048
71. Makide K, Kitamura H, Sato Y, Okutani M, Aoki J. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat (2009) 89:135-9. doi:10.1016/j.prostaglandins.2009.04.009
72. Sevastou I, Kaffe E, Mouratis M-A, Aidinis V. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA2/LPC and ATX/LPA axes. Biochim Biophys Acta (2013) 1831:42-60. doi:10.1016/j.bbalip.2012.07.019
73. Knowlden S, Georas SN. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J Immunol (2014) 192:851-7. doi:10.4049/jimmunol.1302831
74. Piñeiro R, Falasca M. Lysophosphatidylinositol signalling: new wine from an old bottle. Biochim Biophys Acta (2012) 1821:694-705. doi:10.1016/j.bbalip.2012.01.009
75. D'Aquilio F, Procaccini M, Izzi V, Chiurchiu' V, Giambra V, Carotenuto F, et al. Activatory properties of lysophosphatidic acid on human THP-1 cells. Inflammation (2007) 30:167-77. doi:10.1007/s10753-007-9034-2
76. Heimerl S, Fischer M, Baessler A, Liebisch G, Sigruener A, Wallner S, et al. Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PLoS One (2014) 9:e111348. doi:10.1371/journal.pone.0111348
77. Moreno-Navarrete JM, Catalan V, Whyte L, Diaz-Arteaga A, Vazquez-Martinez R, Rotellar F, et al. The L-a-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes (2012) 61:281-91. doi:10.2337/db11-0649
78. Lee H, Liao JJ, Graeler M, Huang MC, Goetzl EJ. Lysophospholipid regulation of mononuclear phagocytes. Biochim Biophys Acta (2002) 1582:175-7. doi:10.1016/S1388-1981(02)00153-1
79. Fuchs B, Schiller J, Wagner U, Häntzschel H, Arnold K. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem (2005) 38:925-33. doi:10.1016/j.clinbiochem.2005.06.006
80. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med (2012) 209:925-33. doi:10.1084/jem.20112012
81. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature (2014) 510:58-67. doi:10.1038/nature13475
82. Gomez-Muñoz A, Presa N, Gomez-Larrauri A, Rivera I-G, Trueba M, Ordoñez M. Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate. Prog Lipid Res (2016) 61:51-62. doi:10.1016/j.plipres.2015.09.002
83. Vandanmagsar B, Youm Y-H, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med (2011) 17:179-88. doi:10.1038/nm.2279
84. Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC, et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem (2004) 279:11320-6. doi:10.1074/jbc.M309262200
85. Simanshu DK, Kamlekar RK, Wijesinghe DS, Zou X, Zhai X, Mishra SK, et al. Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids. Nature (2013) 500:463-7. doi:10.1038/nature12332
86. Józefowski S, Czerkies M, Lukasik A, Bielawska A, Bielawski J, Kwiatkowska K, et al. Ceramide and ceramide 1-phosphate are negative regulators of TNF-a production induced by lipopolysaccharide. J Immunol (2010) 185:6960-73. doi:10.4049/jimmunol.0902926
87. Hankins JL, Fox TE, Barth BM, Unrath KA, Kester M. Exogenous ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine expression. J Biol Chem (2011) 286:44357-66. doi:10.1074/jbc.M111.264010
88. Zhang Q-J, Holland WL, Wilson L, Tanner JM, Kearns D, Cahoon JM, et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes (2012) 61:1848-59. doi:10.2337/db11-1399
89. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest (2009) 119:1871-9. doi:10.1172/JCI38575
90. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol (2011) 11:403-15. doi:10.1038/nri2974
91. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol (2012) 30:69-94. doi:10.1146/annurev-immunol-020711-075011
92. Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov (2013) 12:688-702. doi:10.1038/nrd4099
93. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 9:883-97. doi:10.1038/nrd3248
94. Chiurchiù V. Novel targets in multiple sclerosis: to oxidative stress and beyond. Curr Top Med Chem (2014) 14:2590-9. doi:10.2174/1568026614666141203143801
95. van Doorn R, Nijland PG, Dekker N, Witte ME, Lopes-Pinheiro MA, van het Hof B, et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol (2012) 124:397-410. doi:10.1007/s00401-012-1014-4
96. Van Doorn R, Van Horssen J, Verzijl D, Witte M, Ronken E, Van Het Hof B, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia (2010) 58:1465-76. doi:10.1002/glia.21021
97. van Doorn R, Lopes Pinheiro MA, Kooij G, Lakeman K, van het Hof B, van der Pol SMA, et al. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J Neuroinflammation (2012) 9:133. doi:10.1186/1742-2094-9-133
98. Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, et al. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J (2009) 23:143-52. doi:10.1096/fj.08-118109
99. Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest (2015) 125:1379-87. doi:10.1172/JCI76369
100. Bamias G, Rivera-Nieves J. Targeting S1P receptors, a new mechanism of action for inflammatory bowel disease therapy. Gastroenterology (2016) 151:1025-7. doi:10.1053/j.gastro.2016.09.025
101. Maccarrone M, Guzmán M, Mackie K, Doherty P, Harkany T. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci (2014) 15:786-801. doi:10.1038/nrn3846
102. Pistis M, Melis M. From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem (2010) 17:1450-67. doi:10.2174/092986710790980014
103. Galve-Roperh I, Chiurchiù V, Díaz-Alonso J, Bari M, Guzmán M, Maccarrone M. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog Lipid Res (2013) 52:633-50. doi:10.1016/j.plipres.2013.05.004
104. Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci (2015) 36:277-96. doi:10.1016/j.tips.2015.02.008
105. Cencioni MT, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One (2010) 5:e8688. doi:10.1371/journal.pone.0008688
106. Chiurchiù V, Rapino C, Talamonti E, Leuti A, Lanuti M, Gueniche A, et al. Anandamide suppresses proinflammatory T cell responses in vitro through type-1 cannabinoid receptor-mediated mTOR inhibition in human keratinocytes. J Immunol (2016) 197:3545-53. doi:10.4049/jimmunol.1500546
107. Ribeiro A, Pontis S, Mengatto L, Armirotti A, Chiurchiù V, Capurro V, et al. A potent systemically active N-acylethanolamine acid amidase inhibitor that suppresses inflammation and human macrophage activation. ACS Chem Biol (2015) 10:1838-46. doi:10.1021/acschembio.5b00114
108. Maestroni GJM. The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. FASEB J (2004) 18:1914-6. doi:10.1096/fj.04-2190fje
109. Gasperi V, Evangelista D, Chiurchiù V, Florenzano F, Savini I, Oddi S, et al. 2-Arachidonoylglycerol modulates human endothelial cell/leukocyte interactions by controlling selectin expression through CB1 and CB2 receptors. Int J Biochem Cell Biol (2014) 51:79-88. doi:10.1016/j.biocel.2014.03.028
110. Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol (2000) 406:R5-7. doi:10.1016/S0014-2999(00)00653-1
111. Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem (2001) 81:715-23. doi:10.1002/jcb.1103
112. Velasco G, Sánchez C, Guzmán M. Endocannabinoids and cancer. Handb Exp Pharmacol (2015) 231:449-72. doi:10.1007/978-3-319-20825-1_16
113. Mazier W, Saucisse N, Gatta-Cherifi B, Cota D. The endocannabinoid system: pivotal orchestrator of obesity and metabolic disease. Trends Endocrinol Metab (2015) 26:524-37. doi:10.1016/j.tem.2015.07.007
114. Steffens S, Pacher P. The activated endocannabinoid system in atherosclerosis: driving force or protective mechanism? Curr Drug Targets (2015) 16:334-41. doi:10.2174/1389450115666141202113225
115. Cani PD, Plovier H, Van Hul M, Geurts L, Delzenne NM, Druart C, et al. Endocannabinoids -at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol (2016) 12:133-43. doi:10.1038/nrendo.2015.211
116. Alhouayek M, Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med (2012) 18:615-25. doi:10.1016/j.molmed.2012.07.009
117. Sido JM, Nagarkatti PS, Nagarkatti M. Role of endocannabinoid activation of peripheral CB1 receptors in the regulation of autoimmune disease. Int Rev Immunol (2015) 34:403-14. doi:10.3109/08830185.2014.921165
118. Maccarrone M. Endocannabinoid signaling and neuroinflammatory diseases. Curr Pharm Des (2008) 14:2252-3. doi:10.2174/138161208785740045
119. Di Marzo V, Stella N, Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci (2015) 16:30-42. doi:10.1038/nrn3876
120. Mecha M, Carrillo-Salinas FJ, Feliú A, Mestre L, Guaza C. Microglia activation states and cannabinoid system: therapeutic implications. Pharmacol Ther (2016) 166:40-55. doi:10.1016/j.pharmthera.2016.06.011
121. Skaper SD, Facci L, Barbierato M, Zusso M, Bruschetta G, Impellizzeri D, et al. Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol (2015) 52:1034-42. doi:10.1007/s12035-015-9253-8
122. Gokoh M, Kishimoto S, Oka S, Sugiura T. 2-Arachidonoylglycerol enhances the phagocytosis of opsonized zymosan by HL-60 cells differentiated into macrophage-like cells. Biol Pharm Bull (2007) 30:1199-205. doi:10.1248/bpb.30.1199
123. Cabral GA, Ferreira GA, Jamerson MJ. Endocannabinoids and the immune system in health and disease. Handb Exp Pharmacol (2015) 231:185-211. doi:10.1007/978-3-319-20825-1_6
124. Lipina C, Hundal HS. Modulation of cellular redox homeostasis by the endocannabinoid system. Open Biol (2016) 6:150276. doi:10.1098/rsob.150276
125. Aizpurua-Olaizola O, Elezgarai I, Rico-Barrio I, Zarandona I, Etxebarria N, Usobiaga A. Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov Today (2017) 22:105-10. doi:10.1016/j.drudis.2016.08.005
126. Chiurchiù V, Cencioni MT, Bisicchia E, De Bardi M, Gasperini C, Borsellino G, et al. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol (2013) 73:626-36. doi:10.1002/ana.23875
127. Chiurchiù V, Lanuti M, Catanzaro G, Fezza F, Rapino C, Maccarrone M. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis (2014) 233:55-63. doi:10.1016/j.atherosclerosis.2013.12.042
128. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain (2007) 130:2543-53. doi:10.1093/brain/awm160
129. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci (2007) 28:180-7. doi:10.1016/j.tips.2007.02.004
130. Chiurchiù V, Leuti A, Maccarrone M. Cannabinoid signaling and neuroinflammatory diseases: a melting pot for the regulation of brain immune responses. J Neuroimmune Pharmacol (2015) 10:268-80. doi:10.1007/s11481-015-9584-2
131. Fernández-Ruiz J, Romero J, Ramos JA. Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington's chorea, Alzheimer's disease, and others. Handb Exp Pharmacol (2015) 231:233-59. doi:10.1007/978-3-319-20825-1_8
132. van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA, et al. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem (2002) 45:3709-20. doi:10.1021/jm020818q
133. Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev (2011) 111:5899-921. doi:10.1021/cr2002799
134. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov (2008) 7:438-55. doi:10.1038/nrd2553
135. De Filippis D, D'Amico A, Cipriano M, Petrosino S, Orlando P, Di Marzo V, et al. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol Res (2010) 61:321-8. doi:10.1016/j.phrs.2009.11.005
136. Witkamp R. Fatty acids, endocannabinoids and inflammation. Eur J Pharmacol (2016) 785:96-107. doi:10.1016/j.ejphar.2015.08.051
137. Weichand B, Weis N, Weigert A, Grossmann N, Levkau B, Brüne B. Apoptotic cells enhance sphingosine-1-phosphate receptor 1 dependent macrophage migration. Eur J Immunol (2013) 43:3306-13. doi:10.1002/eji.201343441
138. Scheel-Toellner D, Wang K, Craddock R, Webb PR, McGettrick HM, Assi LK, et al. Reactive oxygen species limit neutrophil life span by activating death receptor signaling. Blood (2004) 104:2557-64. doi:10.1182/blood-2004-01-0191
139. McArthur S, Gobbetti T, Kusters DH, Reutelingsperger CP, Flower RJ, Perretti M. Definition of a novel pathway centered on lysophosphatidic acid to recruit monocytes during the resolution phase of tissue inflammation. J Immunol (2015) 195:1139-51. doi:10.4049/jimmunol.1500733
140. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J (2003) 17:1411-21. doi:10.1096/fj.02-1038com